Versigent (VGNT) Q2 2026 earnings summary

Executive summary

• Net sales reached $2,444 million in Q2 2026, up 11% year-over-year, with adjusted net sales growth of 5%.

• Adjusted EBITDA rose 25% to $272 million, with margin expanding to 11.1%.

• Net income attributable to shareholders was $118 million, up 10% year-over-year.

• Initiated first quarterly dividend of $0.13 per share and authorized a $250 million share repurchase program.

• Completed spin-off from Aptiv in April 2026, establishing independent operations and public listing.

Financial highlights

• Q2 2026 net sales: $2,444 million (+11% YoY); adjusted net sales: $2,308 million (+5% YoY).

• Adjusted EBITDA: $272 million (11.1% margin, +120 bps YoY).

• Net income: $118 million; adjusted diluted EPS: $1.92; diluted EPS: $1.64.

• Free cash flow: $107 million, flat year-over-year, including $22 million in separation-related costs.

• Operating income increased to $199 million from $131 million in Q2 2025.

Outlook and guidance

• Full-year 2026 net sales guidance raised to $9,400–$9,600 million (from $9,100–$9,400 million).

• Adjusted EBITDA guidance reaffirmed at $950–$1,030 million; free cash flow at $200–$300 million.

• Cumulative free cash flow of ~$1 billion expected between 2026–2028.

• Expect ~2% adjusted net sales growth for 2026, above market, driven by strong launches and customer positioning.

• Ongoing restructuring and cost optimization to align with regional production and support investment in advanced technologies.